Halofugine prevents cutaneous graft versus host disease by suppression of Th17 differentiation

Hematology

Volumn 17, Issue 5, 2012, Pages 261-267

  Cheng, Hai ^a   Tian, Jing ^b   Zeng, Lingyu ^a   Pan, Bin ^a   Li, Zhenyu ^a   Song, Guoliang ^a   Chen, Wei ^a   Xu, Kailin ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b XUZHOU CHILDREN S HOSPITAL   (China)

Author keywords

Cutaneous graft versus host disease; Halofuginone; Th17 cells

Indexed keywords

CD4 ANTIGEN; DIMETHYL SULFOXIDE; GAMMA INTERFERON; HALOFUGINONE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN DISEASE; SKIN MANIFESTATION; SPLEEN CELL; TH17 CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CHRONIC DISEASE; CYTOKINES; FEMALE; GRAFT VS HOST DISEASE; MALE; MICE; MICE, INBRED BALB C; PIPERIDINES; QUINAZOLINONES; SKIN DISEASES; TH17 CELLS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84866133454     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000016     Document Type: Article

References (48)

1. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464-72. PMID: 2207321.
2. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Ann Rev Med. 2003;54:29-52. PMID: 12359826.
3. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340-52. PMID: 17438575.
4. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8:575-81. PMID: 12042807.
5. Macindoe I, Glockner L, Vukasin P, Stennard FA, Costa MW, Harvey RP, et al. Conformational stability and DNA binding specificity of the cardiac T-box transcription factor Tbx20. J Mol Biol. 2009;389:606. PMID: 19414016.
6. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787-93. PMID: 8893001.
7. Murph KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol. 2002;2:933-44. PMID: 12461566.
8. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441:235-8. PMID: 16648838.
9. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888-98. PMID: 19710487.
10. Loong CC, Hsieh HG, Lui WY, Chen A, Lin CY. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol. 2002;197:322-32. PMID: 12115878.
11. Vanaudenaerde BM, Dupont LJ, Wuyts WA, Verbeken EK, Meyts I, Bullens DM, et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J. 2006; 27:779-87.
12. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, D'Addio F, Mfarrej B, Donnarumma M, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med. 2008;205:3133-44. PMID: 19047438.
13. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000;105:1289. PMID: 10792004.
14. Hill GR, Olver SD, Kuns RD, Varelias A, Raffelt NC, Don AL, et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood. 2010;116:819-28. PMID: 20435882.
15. Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I, et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood. 2008; 112:2101-10. PMID: 18596226.
16. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood. 2009;113:1365-74. PMID: 18957685.
17. Lexberg MH, Taubner A, Förster A, Albrecht I, Richter A, Kamradt T, et al. Th memory for interleukin-17 expression is stable in vivo. Eur J Immunol. 2008;38:2654-64. PMID: 18825747.
18. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005;22:285-94. PMID: 15780986.
19. He D, Wu L, Kim HK, Li H, Elmets CA, Xu H. CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol. 2006; 177:6852-58. PMID: 17082599.
20. Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, Grogan JL, et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol. 2009;10:66-74. PMID: 19029905.
21. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB, et al. Identification of an IL-17-producing NK1.1neg iNKT cell population involved in airway neutrophilia. J Exp Med. 2007; 204:995-1001. PMID: 17470641.
22. Lee KA, Kang MH, Lee YS, Kim YJ, Kim DH, Ko HJ, et al. A distinct subset of natural killer T cells produces IL-17, contributing to airway infiltration of neutrophils but not to airway hyperreactivity. Cell Immunol. 2008;251:50-55. PMID: 18423430.
23. Mrabet-Dahbi S, Metz M, Dudeck A, Zuberbier T, Maurer M. Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Exp Dermatol. 2009;18:437-44. PMID: 19382314.
24. Song C, Luo L, Lei Z, Li B, Liang Z, Liu G, et al. IL-17-producing alveolar macrophages mediate allergic lung inflammation related to asthma. J Immunol. 2008;181:6117-24. PMID: 18941201.
25. Li L, Huang L, Vergis AL, Ye H, Bajwa A, Narayan V, et al. IL-17 produced by neutrophils regulates IFN-γ-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest. 2010;120:331-42. PMID: 20038794.
26. Pines M, Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol. 1998;30:445-50. PMID: 9522159.
27. Sundrud MS, Koralov SB, Feuerer M, Calado DP, Kozhaya AE, Rhule-Smith A, et al. Halofuginone inhibits Th17 cell differentiation by activating the amino acid starvation response. Science. 2009;324:1334-8. PMID: 19498172.
28. Stecklair KP, Hamburger DR, Egorin MJ, Parise RA, Covey JM, Eiseman JL. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol. 2001;48:375-82. PMID: 11761455.
29. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J, Jr, Crawford JM, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor h antigens and endotoxin. Blood. 1996;88:3230-9. PMID: 8963063.
30. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med. 2006;13:2785-91. PMID: 17130300.
31. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donorand host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005;105:2227-34. PMID: 15522961.
32. Borsotti C, Franklin AR, Lu SX, Kim TD, Smith OM, Suh D, et al. Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood. 2007;110:783-6. PMID: 17395784.
33. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-32. PMID: 16200070.
34. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, et al. Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med. 2006;203: 2715-25. PMID: 17101734.
35. Nakae S, Iwakura Y, Suto H, Galli SJ. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol. 2007;81:1258-68. PMID: 17307864.
36. de Figueiredo-Pontes LL, Assis PA, Santana-Lemos BA, Jácomo RH, Lima AS, Garcia AB, et al. Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor Beta signaling pathway. PLoS One. 2011;6:e26713. PMID: 22053203.
37. Elkin M, Miao HQ, Nagler A, Aingorn E, Reich R, Hemo I, et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J. 2000;14:2477-85. PMID: 11099465.
38. Leiba M, Cahalon L, Shimoni A, Lider O, Zanin-Zhorov A, Hecht I, et al. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. J Leukoc Biol. 2006;80:399-406. PMID: 16769768.
39. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;7:1653-61. PMID: 18219280.
40. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008; 5:1207-11. PMID: 18200064.
41. Pidala J, Vogelsang G, Martin P, Chai X, Storer B, Pavletic S, et al. Overlap subtype of chronic graft vs. host disease is associated with adverse prognosis, functional impairment, and inferior patient reported outcomes: a chronic graft vs. host disease Consortium study. Haematologica. 2012;97(3):451-8.
42. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med. 1987;166:1280-9. PMID: 3316469.
43. Wall DA, Sheehan KC. The role of tumor necrosis factor alpha and interferon gamma in graft-versus-host disease and related immunodeficiency. Transplantation. 1994;57:273-9. PMID: 8310520.
44. Gaffen SL. Structure and signaling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556-67. PMID: 19575028.
45. O'Connor W, Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009; 10:603-9. PMID: 19448631.
46. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol. 2011;12:255-63. PMID: 21278737.
47. Palmer MT, Weaver CT. Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat Immunol. 2010;11:36-40. PMID: 20016508.
48. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, et al. Induction of IL-17+ T cell trafficking and development by IFNgamma: Mechanism and pathological relevance in psoriasis. J Immunol. 2008;181:4733-41. PMID: 18802076.